ClinicalTrials.gg
RecruitingNCT05793996ID-HFpEFUpdated Jun 24, 2026

The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)

A Phase 4 interventional study of Ferinject and Diet therapy in Chronic Heart Failure and Iron Deficiency, Latent, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Planned enrollment
23rd of 40
100 · median 134
Started
2023
with 1 other
Phase 4
18 of 40
6 open now
Registered
31st of 40
by date

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 23rd largest by planned enrollment, is one of 2 that started in 2023, is one of 18 in phase 4, and was the 31st registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.

Read the detailed description

The prevalence of HFpEF among patients admitted to cardiology hospitals will be studied. The study will include patients with NYHA II-III who have signed an informed consent that meets the inclusion/exclusion criteria. The effectiveness of intravenous administration of iron carboxymaltose (Ferinject ® ) to correct iron deficiency and improve the clinical course of HFpEF will be evaluated. A group without iron deficiency will be recruited as a control group (n=30).

03

Conditions studied

  • Chronic Heart Failure
  • Iron Deficiency, Latent

Browse trials for

Keywords

  • HFpEF
  • iron deficiency
  • ferric carboxymaltose
  • Ferinject
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed to participate in the study;
  • In (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);
  • (LVEF) ≥50%; objective signs of structural and/or functional disorders of the heart consistent with the presence of LV diastolic dysfunction/increased LV filling pressure, including elevated levels of natriuretic peptide;
  • Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%;
  • Screening (Hb) at the time of switching on ( 90-150 g/l).

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled arterial hypertension;
  • Аnemia not related to iron deficiency;
  • Аnemia with a level of less than 90 g/l;
  • Less than 1 year after acute myocardial infarction;
  • Less than 1 year after acute cerebral circulation disorder;
  • Less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology;
  • Chronic alcoholism (including alcoholic heart disease), mental disorders;
  • Severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency ( less than 15 ml/min/1.73 m2);
  • Known active infection, bleeding, active ;
  • Severe diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);
  • Severe bronchial asthma, in the acute stage;
  • Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;
  • Blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Experimental: 1

    Drug: Ferinject ® (Ferric carboxymaltose)

    Drug: Ferinject

  • Other
    Comparison Group: 2

    Diet therapy, without drug therapy

    Other: Diet therapy

  • No intervention
    Control Group: 3

    Without therapy

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.

    Also known as: Ferric carboxymaltose

  • OtherDiet therapy

    Patients will receive diet therapy to correct latent iron deficiency

06

What researchers measure

Primary outcomes

  1. Primary Outcome (Combined)

    Change of 5 or more points on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (0-100 points)+change in test distance with a 6-minute walk (6MWD - 150 meters or more) by 35 meters or more. An increase in the number of points by 5 on the Kansas City Cardiomyopathy Questionnaire scale, increasing the distance on the 6-minute walk test by 35 meters means a better result. The absence of changes/decrease in the number of points on the Kansas City Cardiomyopathy Questionnaire scale, the absence of changes/decrease in the distance in the 6-minute walking test means the worst result.

    Time frame: 12 months

Secondary outcomes

  1. Changing by 5 or more points on the Kansas City Cardiomyopathy Questionnaire (KCCQ 0-100 points)

    Change of 5 or more points in the Kansas City Cardiomyopathy Questionnaire (KCCQ) (0-100 points). An increase in the number of points by 5 on the Kansas City Cardiomyopathy Questionnaire scale means a better result. The absence of changes/decrease in the number of points on the Kansas City Cardiomyopathy Questionnaire scale means the worst result.

    Time frame: 6 months

  2. Changing in test distance with a 6-minute walk (6MWD 300 meters or more) of 35 meters

    Change in the distance when testing a 6-minute walk by 35 meters or more. An increase the distance on the 6-minute walk test by 35 meters or more means a better result. The absence of changes/decrease in the distance in the 6-minute walking test means the worst result.

    Time frame: 6 months

  3. Changing functional class of chronic heart failure (CHF) by New York Heart Association (NYHA I-IV functional classes)

    Reduction of the functional class of CHF according to New York Heart Association by 1point means a better result. No changes or an increase in the functional class means a worse result.

    Time frame: 6 months

  4. Hospitalization for heart failure and death from all causes

    The absence of hospitalizations for heart failure and death from all causes means a better result. Hospitalization and death from all causes means the worst result.

    Time frame: 12 months

  5. Changing by 5 or more points according to the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) (0-105 points).

    A decrease of 5 or more points on the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) means a better result. The absence of changes/increase in the number of points on the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) means the worst result.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 31, 2023
StartActual
Apr 28, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05793996
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Apr 28, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 24, 2026

Study contacts

Olga V. Tukish, Ph.D.
Contact
olgatukish@yandex.ru
+79069476343
Alla A. Garganeeva, M.D.
principal investigator · Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion